Nowara Elżbieta, Działach Eliza, Grajek Mateusz, Kolosza Zofia, Huszno Joanna
Department of Health Sciences, Jan Dlugosz University of Humanities and Natural Sciences, Czestochowa, Poland|.
Department of Public Health, Silesian Medical University, Katowice, Poland.
Contemp Oncol (Pozn). 2021;25(3):147-152. doi: 10.5114/wo.2021.109362. Epub 2021 Sep 21.
Patients with cancer undergoing active systemic anticancer treatment (chemotherapy, immunotherapy, targeted, or combination therapy) are at greater risk of COVID-19 infection than persons without cancer. In this paper, the authors analyse the spread of the coronavirus among cancer patients undergoing systemic therapy, and the impact of COVID-19 infection on the continuation of cancer treatment and its outcome at one community hospital in a mid-sized city in the south of Poland.
Nasopharyngeal swab was the only collection method used to obtain specimens for testing via real-time reverse-transcriptase polymerase chain reaction (RT-PCR). Only those with positive RT-PCR results were considered as confirmed SARS-CoV-2 cases. We analysed the medical records of patients quarantined in a hospital clinical oncology ward due to confirmed COVID-19 infection in one member of the group. Qualitative measures are presented as the percentage of their occurrence, and these were evaluated with Fisher's test. Differences were considered significant at < 0.05.
Cancer patients had more frequent confirmed COVID-19 infection than other patients (3.7% vs. 1.2%). Among cancer patients COVID-19 infection was significantly more frequent in women than in men, = 0.005. The fatality rate was 27.3% in cancer patients undergoing active anticancer therapy, compared to 3% in the general Polish population. Neither heparin nor G-CSF use had any influence on COVID-19 infection.
In this analysis, the only significant negative factor for COVID-19 infection was female sex, RR (95% CI) = 4.5 (1.3-15.8), ( = 0.005), and this was attributable to individual behaviour.
正在接受积极全身抗癌治疗（化疗、免疫治疗、靶向治疗或联合治疗）的癌症患者比无癌症患者感染新冠病毒的风险更高。在本文中，作者分析了冠状病毒在接受全身治疗的癌症患者中的传播情况，以及新冠病毒感染对波兰南部一个中等城市的一家社区医院中癌症治疗的持续进行及其结果的影响。
鼻咽拭子是用于通过实时逆转录聚合酶链反应（RT-PCR）检测获取标本的唯一采集方法。只有RT-PCR结果呈阳性的患者才被视为确诊的新冠病毒病例。我们分析了因该组一名成员确诊新冠病毒感染而被隔离在医院临床肿瘤病房的患者的病历。定性指标以其出现的百分比表示，并通过Fisher检验进行评估。差异在<0.05时被认为具有统计学意义。
癌症患者确诊新冠病毒感染的频率高于其他患者（3.7%对1.2%）。在癌症患者中，女性新冠病毒感染的频率明显高于男性，P = 0.005。正在接受积极抗癌治疗的癌症患者的死亡率为27.3%，而波兰普通人群的死亡率为3%。使用肝素和粒细胞集落刺激因子（G-CSF）均对新冠病毒感染没有任何影响。
在本分析中，新冠病毒感染的唯一显著负面因素是女性，相对危险度（RR，95%置信区间）= 4.5（1.3 - 15.8），（P = 0.005），这归因于个体行为。
